Search Results - Keyvan Rezai
- Showing 1 - 2 results of 2
-
1
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers. by Paul H Cottu, Jacques Bonneterre, Andrea Varga, Mario Campone, Alexandra Leary, Anne Floquet, Dominique Berton-Rigaud, Marie-Paule Sablin, Anne Lesoin, Keyvan Rezai, François M Lokiec, Catherine Lhomme, Jacques Bosq, Alice S Bexon, Erard M Gilles, Stefan Proniuk, Veronique Dieras, David M Jackson, Alexander Zukiwski, Antoine Italiano
Published in PLoS ONE (2018-01-01)Get full text
Article -
2
A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers by Filippo Spriano, Giulio Sartori, Jacopo Sgrignani, Laura Barnabei, Alberto J. Arribas, Matilde Guala, Ana Maria Carrasco Del Amor, Meagan R. Tomasso, Chiara Tarantelli, Luciano Cascione, Gaetanina Golino, Maria E Riveiro, Roberta Bortolozzi, Antonio Lupia, Francesco Paduano, Samuel Huguet, Keyvan Rezai, Andrea Rinaldi, Francesco Margheriti, Pedro Ventura, Greta Guarda, Giosuè Costa, Roberta Rocca, Alberto Furlan, Luuk M. Verdonk, Paolo Innocenti, Nathaniel I. Martin, Giampietro Viola, Christoph Driessen, Emanuele Zucca, Anastasios Stathis, Digvijay Gahtory, Maurits van den Nieuwboer, Beat Bornhauser, Stefano Alcaro, Francesco Trapasso, Susana Cristobal, Shae B. Padrick, Natalina Pazzi, Franco Cavalli, Andrea Cavalli, Eugenio Gaudio, Francesco Bertoni
Published in Haematologica (2024-06-01)Get full text
Article